GOTHENBURG, Sweden, September 22, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will be participating in two investor meetings, the first of which takes place today, September 22.
The information in the press release is intended for investors.
Isofol is developing arfolitixorin – a proprietary clinical-stage drug candidate designed to enhance the efficacy of established cancer treatments. Based on extensive clinical research, arfolitixorin is now being tested in a phase Ib/II clinical study with an optimized dose regimen, initially conducted at the German University Hospital Charité. The drug candidate has the potential to fill a known treatment gap in cancer care.
During two investor meetings, in September and November, Isofol’s CEO Petter Segelman Lindqvist will present the company and the development of arfolitixorin at the following events:
- September 22, BioStock’s “Investing in Life Science – from seed to success” in Stockholm, Sweden.
- November 4–5, BioStock’s Life Science Summit 2026 in Lund, Sweden.
The presentations will be available afterwards via Isofol’s website.
Colorectal cancer is the third most common form of cancer globally, and the second most common cause of cancer-related death, according to the World Health Organization (WHO). The need for new treatments in the field is, therefore, highly significant.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on September 22, 2026.
About Isofol
Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company’s drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world’s third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.
